Issue link: https://uberflip.scri.com/i/1531660
0206/25SCR020-1/R3RGB Abstract & Presentation Calendar Tandem Transplantation and Cellular Therapy Meetings 2025 4 Thursday Wednesday Friday Saturday THURSDAY, FEBRUARY 13 TH 6:45pm - 7:45pm Honolulu Time (continued) Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 6:45 - 7:45pm Exhibit Hall 3 Poster 290 Prophylactic Dexamethasone Rescues Unrestrained Lymphocyte Expansion in Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma Turner J Turner J, Forsberg PA, Nicholson S, Schade H, Matous J, Gregory TK Poster Session: Engineered Immune Cells (CAR-T, NK, TCR): Clinical - Immune Effector Cells for Heme Malignancies 6:45 - 7:45pm Exhibit Hall 3 Poster 148 NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival Valtis Y Battiwalla M, Majhail N, Malik S, Mathews J, Mountjoy L, Shaughnessy P Poster Session: Acute and Chronic Leukemia (AML, MDS, MPD ALL, CML,) - Clinical 6:45 - 7:45pm Exhibit Hall 3 Poster 150 Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) Faramand R Battiwalla M, Majhail N, Malik S, Mathews J, Mountjoy L, Shaughnessy P Poster Session: Acute and Chronic Leukemia (AML, MDS, MPD ALL, CML,) - Clinical 6:45 - 7:45pm Exhibit Hall 3 Poster 154 Tyrosine Kinase Inhibitor (TKI) Maintenance Improves Remission Durability in Philadelphia- Chromosome Acute Lymphoblastic Leukemia (Ph+ ALL) Following Brexucabtagene Autoleucel (Brexu- cel) Othman T Battiwalla M, Majhail N, Malik S, Mathews J, Mountjoy L, Shaughnessy P Poster Session: Acute and Chronic Leukemia (AML, MDS, MPD ALL, CML,) - Clinical 6:45 - 7:45pm Exhibit Hall 3 Poster 285 KMT2Ar Adversely Impacts Brexucabtagene Autoleucel (Brexu-cel) Outcome in Adults with Relapsed/ Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia. Leonard J Battiwalla M, Majhail N, Malik S, Mathews J, Mountjoy L, Shaughnessy P Poster Session: Engineered Immune Cells (CAR-T, NK, TCR): Clinical - Immune Effector Cells for Heme Malignancies 6:45 - 7:45pm Exhibit Hall 3 Poster 721 Factors Associated with Clinical Trial Participation in Adult Hematopoietic Stem Cell Transplantation (HSCT) Recipients: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis Gray T Battiwalla M Poster Session: Research Nursing Abstracts 6:45 - 7:45pm Exhibit Hall 3 Poster 567 Clinical Activity of P-BCMA-ALLO1, an Allogeneic BCMA Targeting CAR-T, in Patients with Relapsed Refractory Multiple Myeloma (RRMM) and Extramedullary Disease Ganguly S Cruz JC, Ramakrishnan A Poster Session: Myeloma - Clinical 6:45 - 7:45pm Exhibit Hall 3 Poster 152 Comparison of Obecabtagene Autoleucel (obe-cel) Versus an External Control Arm (ECA) in Adult Patients (pts) with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Sandhu K Shaughnessy P Poster Session: Acute and Chronic Leukemia (AML, MDS, MPD ALL, CML,) - Clinical 6:45 - 7:45pm Exhibit Hall 3 Poster 292 Deep Molecular Remission Predicts Better Clinical Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene Autoleucel (obe-cel) Logan A Shaughnessy P Poster Session: Engineered Immune Cells (CAR-T, NK, TCR): Clinical - Immune Effector Cells for Heme Malignancies